NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$34.54 +1.07 (+3.20 %)
(As of 05/25/2018 07:20 AM ET)
Previous Close$33.47
Today's Range$33.01 - $34.80
52-Week Range$16.50 - $39.51
Volume391,153 shs
Average Volume355,114 shs
Market Capitalization$1.30 billion
P/E Ratio-6.91
Dividend YieldN/A
BetaN/A

About Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical logoBiohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:BHVN
CUSIPN/A
Phone203-404-0410

Debt

Debt-to-Equity RatioN/A
Current Ratio6.80
Quick Ratio6.80

Price-To-Earnings

Trailing P/E Ratio-6.91
Forward P/E Ratio-7.18
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book12.47

Profitability

EPS (Most Recent Fiscal Year)($5.00)
Net Income$-127,190,000.00
Net MarginsN/A
Return on Equity-137.13%
Return on Assets-120.17%

Miscellaneous

Employees42
Outstanding Shares38,880,000

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical (NYSE:BHVN) posted its earnings results on Tuesday, May, 15th. The company reported ($2.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.12) by $1.21. View Biohaven Pharmaceutical's Earnings History.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Biohaven Pharmaceutical.

What price target have analysts set for BHVN?

6 brokerages have issued 1-year price objectives for Biohaven Pharmaceutical's shares. Their forecasts range from $25.00 to $48.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $38.00 in the next twelve months. View Analyst Ratings for Biohaven Pharmaceutical.

What are Wall Street analysts saying about Biohaven Pharmaceutical stock?

Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
  • 1. Canaccord Genuity analysts commented, "We continue to like BHVN stock heading into additional rimegepant data later this year and are reiterating our BUY rating. Our BHVN valuation continues to include no specific value for BHV-3500 (acute treatment and migraine prevention; Phase 1 trial initiation in 1H18) or other products ex-sublingual riluzole for amyotrophic lateral sclerosis (ALS). on oral anti-CGRPs extends beyond acute treatment Some key opinion leaders (KOLs) that we spoke with at the recent Neurology (AAN) meeting in April were enthusiastic about the potential for oral anti-CGRPs in migraine prevention. These physicians also said they would be closely watching oral anti-CGRPs for the acute treatment of migraine such as rimegepant, if approved, for an early read on real-world usage of oral anti-CGRPs in potentially preventing migraines." (5/22/2018)
  • 2. Needham & Company LLC analysts commented, "Biohaven released financial results yesterday and we spoke w/ mgmt for an update. Top-line results from remaining Phase 3 Migraine trials of rimegepant (1-year safety trial and orally disintegrating tablet [ODT] trial) are still expected 4Q18. We expect data from these trials as well as from the ubrogepant open-label long-term extension trial later this yr to provide a more complete picture of safety and efficacy profiles. We currently view both the Biohaven and Allergan drugs as competitive, but acknowledge lower pain figures for rimegepant at 2hrs after administration. Mgmt is exploring partnership options for rimegepant, although we currently assume in our model that the drug will be commercialized by Biohaven. Reiterate BUY." (5/16/2018)
  • 3. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (5/16/2018)

Who are some of Biohaven Pharmaceutical's key competitors?

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the folowing people:
  • Dr. Vladimir Coric, CEO & Director (Age 47)
  • Mr. James Engelhart, Chief Financial Officer (Age 54)
  • Dr. Robert Berman, Chief Medical Officer (Age 55)
  • Dr. Charles Conway, Chief Scientific Officer (Age 56)
  • Mr. John Tilton, Chief Commercial Officer (Age 50)

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Has Biohaven Pharmaceutical been receiving favorable news coverage?

News coverage about BHVN stock has trended very positive on Friday, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 0.65 on Accern's scale. They also gave media headlines about the company an impact score of 48.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.24%), VHCP Management II LLC (3.86%), Eagle Asset Management Inc. (2.98%), Foresite Capital Management IV LLC (2.36%), Eventide Asset Management LLC (0.89%) and Rock Springs Capital Management LP (0.90%). Company insiders that own Biohaven Pharmaceutical stock include Albert Cha, Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Millennium Management LLC and Eagle Asset Management Inc.. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Foresite Capital Management IV LLC, Northern Trust Corp, ARS Investment Partners LLC, Sphera Funds Management LTD., Eventide Asset Management LLC, Rock Springs Capital Management LP and Schwab Charles Investment Management Inc.. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Albert Cha, James Engelhart and Robert Berman. View Insider Buying and Selling for Biohaven Pharmaceutical.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $34.54.

How big of a company is Biohaven Pharmaceutical?

Biohaven Pharmaceutical has a market capitalization of $1.30 billion. The company earns $-127,190,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Biohaven Pharmaceutical employs 42 workers across the globe.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 234 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


MarketBeat Community Rating for Biohaven Pharmaceutical (BHVN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biohaven Pharmaceutical (NYSE:BHVN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Biohaven Pharmaceutical in the last 12 months. Their average twelve-month price target is $38.00, suggesting that the stock has a possible upside of 10.02%. The high price target for BHVN is $48.00 and the low price target for BHVN is $25.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.833.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.00$37.8333$39.50$40.80
Price Target Upside: 10.02% upside50.43% upside26.60% upside70.43% upside

Biohaven Pharmaceutical (NYSE:BHVN) Consensus Price Target History

Price Target History for Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical (NYSE:BHVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/22/2018Canaccord GenuityReiterated RatingBuy$35.00LowView Rating Details
5/16/2018Needham & Company LLCReiterated RatingBuy$36.00LowView Rating Details
4/5/2018BarclaysDowngradeOverweight ➝ Equal Weight$30.00 ➝ $25.00MediumView Rating Details
3/26/2018Piper Jaffray CompaniesReiterated RatingBuyHighView Rating Details
10/3/2017William BlairReiterated RatingOutperformLowView Rating Details
10/3/2017Morgan StanleyReiterated RatingOverweight ➝ Overweight$47.00 ➝ $38.00HighView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Biohaven Pharmaceutical (NYSE:BHVN) Earnings History and Estimates Chart

Earnings by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical (NYSE:BHVN) Earnings Estimates

2018 EPS Consensus Estimate: ($4.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.69)($0.69)($0.69)
Q2 20181($0.98)($0.98)($0.98)
Q3 20181($1.09)($1.09)($1.09)
Q4 20181($1.25)($1.25)($1.25)

Biohaven Pharmaceutical (NYSE BHVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018        
5/15/2018Q1 2018($1.1150)($2.32)ViewN/AView Earnings Details
3/6/2018Q4 2017($1.33)($0.75)ViewN/AView Earnings Details
11/14/2017Q3 2017($1.22)($1.19)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.57)($1.78)ViewN/AView Earnings Details
6/16/2017Q1 2017($0.88)($1.74)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Biohaven Pharmaceutical (NYSE:BHVN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Biohaven Pharmaceutical (NYSE BHVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.20%
Institutional Ownership Percentage: 80.24%
Insider Trading History for Biohaven Pharmaceutical (NYSE:BHVN)
Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical (NYSE BHVN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Robert BermanInsiderSell35,000$26.82$938,700.00View SEC Filing  
5/7/2018James EngelhartCFOSell2,500$27.67$69,175.00View SEC Filing  
4/10/2018Robert BermanInsiderSell35,000$24.66$863,100.00View SEC Filing  
3/12/2018Robert BermanInsiderSell35,000$30.11$1,053,850.00View SEC Filing  
3/1/2018Kimberly GentileVPSell5,000$32.87$164,350.00View SEC Filing  
2/21/2018James EngelhartCFOSell538$29.60$15,924.803,038View SEC Filing  
2/12/2018Robert BermanInsiderSell35,000$30.42$1,064,700.00View SEC Filing  
2/1/2018Kimberly GentileVPSell5,000$32.78$163,900.005,000View SEC Filing  
1/31/2018Gregory BaileyDirectorSell50,000$33.71$1,685,500.002,516,701View SEC Filing  
1/22/2018Gregory BaileyDirectorSell49,000$30.76$1,507,240.002,583,289View SEC Filing  
1/22/2018James EngelhartCFOSell10,000$32.50$325,000.0013,576View SEC Filing  
1/19/2018Portage Biotech Inc.Major ShareholderSell35,119$30.03$1,054,623.57View SEC Filing  
1/18/2018Declan DooganDirectorSell128,058$26.95$3,451,163.102,583,289View SEC Filing  
1/16/2018Gregory BaileyDirectorSell40,000$26.52$1,060,800.00View SEC Filing  
1/12/2018Declan DooganDirectorSell121,942$26.78$3,265,606.76View SEC Filing  
1/10/2018Declan DooganDirectorSell40,362$27.69$1,117,623.78View SEC Filing  
1/10/2018Robert BermanInsiderSell35,000$27.52$963,200.00View SEC Filing  
1/9/2018Portage Biotech Inc.Major ShareholderSell84,881$30.06$2,551,522.866,278,504View SEC Filing  
1/5/2018Portage Biotech Inc.Major ShareholderSell22,996$30.03$690,569.886,278,504View SEC Filing  
1/4/2018Gregory BaileyDirectorSell50,000$28.71$1,435,500.001,187,275View SEC Filing  
1/3/2018Portage Biotech Inc.Major ShareholderSell35,650$28.61$1,019,946.50124,371View SEC Filing  
1/2/2018Kimberly GentileVPSell5,000$27.60$138,000.005,000View SEC Filing  
12/20/2017Gregory BaileyDirectorSell39,430$26.31$1,037,403.301,234,077View SEC Filing  
12/19/2017Robert BermanInsiderSell10,000$24.10$241,000.00View SEC Filing  
12/11/2017Robert BermanInsiderSell25,000$21.28$532,000.00View SEC Filing  
12/1/2017Kimberly GentileVPSell5,000$21.99$109,950.00View SEC Filing  
11/30/2017Gregory BaileyDirectorSell9,970$25.48$254,035.601,262,759View SEC Filing  
11/27/2017Gregory BaileyDirectorSell20,600$25.92$533,952.001,289,699View SEC Filing  
11/24/2017Gregory BaileyDirectorSell600$26.02$15,612.001,289,699View SEC Filing  
11/14/2017Robert BermanInsiderSell160,000$25.76$4,121,600.00View SEC Filing  
11/10/2017James EngelhartCFOSell30,538$26.58$811,700.0425,176View SEC Filing  
11/9/2017Robert BermanInsiderSell27,423$26.60$729,451.80View SEC Filing  
11/1/2017John TiltonInsiderSell30,000$29.25$877,500.0030,000View SEC Filing  
11/1/2017Kimberly GentileVPSell5,000$29.28$146,400.005,000View SEC Filing  
11/1/2017Vlad CoricCEOSell150,000$29.41$4,411,500.00View SEC Filing  
5/9/2017Albert ChaDirectorBuy470,000$17.00$7,990,000.00View SEC Filing  
5/9/2017James EngelhartCFOBuy2,500$17.00$42,500.003,576View SEC Filing  
5/9/2017Robert BermanInsiderBuy50$17.00$850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biohaven Pharmaceutical (NYSE BHVN) News Headlines

Source:
DateHeadline
Biohaven Pharmaceuticals (BHVN) Buy Rating Reaffirmed at Canaccord GenuityBiohaven Pharmaceutical's (BHVN) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - May 22 at 9:18 PM
Zacks: Analysts Anticipate Biohaven Pharmaceutical (BHVN) Will Post Earnings of -$0.99 Per ShareZacks: Analysts Anticipate Biohaven Pharmaceutical (BHVN) Will Post Earnings of -$0.99 Per Share
www.americanbankingnews.com - May 19 at 9:16 PM
Q3 2018 EPS Estimates for Biohaven Pharmaceutical Boosted by Analyst (BHVN)Q3 2018 EPS Estimates for Biohaven Pharmaceutical Boosted by Analyst (BHVN)
www.americanbankingnews.com - May 18 at 7:56 AM
Biohaven Pharmaceutical (BHVN) Receives Consensus Rating of "Hold" from BrokeragesBiohaven Pharmaceutical (BHVN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 18 at 3:48 AM
Biohaven Pharmaceutical (BHVN) PT Set at $35.00 by Canaccord GenuityBiohaven Pharmaceutical (BHVN) PT Set at $35.00 by Canaccord Genuity
www.americanbankingnews.com - May 17 at 6:36 PM
Biohaven Pharmaceutical (BHVN) Rating Reiterated by Needham & Company LLCBiohaven Pharmaceutical (BHVN) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - May 16 at 9:24 PM
Zacks Investment Research Downgrades Biohaven Pharmaceutical (BHVN) to SellZacks Investment Research Downgrades Biohaven Pharmaceutical (BHVN) to Sell
www.americanbankingnews.com - May 16 at 6:36 PM
Biohaven Pharmaceutical (BHVN) Issues Quarterly  Earnings Results, Misses Estimates By $1.20 EPSBiohaven Pharmaceutical (BHVN) Issues Quarterly Earnings Results, Misses Estimates By $1.20 EPS
www.americanbankingnews.com - May 16 at 1:18 PM
What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltd’s (NYSE:BHVN) Earnings Trend?What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltd’s (NYSE:BHVN) Earnings Trend?
finance.yahoo.com - May 16 at 9:26 AM
Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business ResultsBiohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results
finance.yahoo.com - May 15 at 5:03 PM
Robert Berman Sells 35,000 Shares of Biohaven Pharmaceutical (BHVN) StockRobert Berman Sells 35,000 Shares of Biohaven Pharmaceutical (BHVN) Stock
www.americanbankingnews.com - May 14 at 7:41 PM
Biohaven Pharmaceutical (BHVN) CFO James Engelhart Sells 2,500 SharesBiohaven Pharmaceutical (BHVN) CFO James Engelhart Sells 2,500 Shares
www.americanbankingnews.com - May 9 at 8:28 PM
Biohaven Pharmaceutical (BHVN) Raised to Hold at ValuEngineBiohaven Pharmaceutical (BHVN) Raised to Hold at ValuEngine
www.americanbankingnews.com - May 3 at 10:32 PM
Zacks: Analysts Anticipate Biohaven Pharmaceutical (BHVN) Will Announce Earnings of -$0.89 Per ShareZacks: Analysts Anticipate Biohaven Pharmaceutical (BHVN) Will Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - May 2 at 11:25 AM
Allergan Hits Another Home Run For 2nd Migraine StudyAllergan Hits Another Home Run For 2nd Migraine Study
seekingalpha.com - April 30 at 9:22 AM
Biohaven Pharmaceutical (BHVN) Given a $34.00 Price Target at Canaccord GenuityBiohaven Pharmaceutical (BHVN) Given a $34.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - April 28 at 9:14 AM
FY2020 Earnings Estimate for Biohaven Pharmaceutical (BHVN) Issued By William BlairFY2020 Earnings Estimate for Biohaven Pharmaceutical (BHVN) Issued By William Blair
www.americanbankingnews.com - April 26 at 11:28 AM
Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of RimegepantBiohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant
seekingalpha.com - April 23 at 8:58 AM
Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of MigraineBiohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine
finance.yahoo.com - April 23 at 8:58 AM
Biohaven Pharmaceutical (BHVN) Given Consensus Recommendation of "Buy" by BrokeragesBiohaven Pharmaceutical (BHVN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 23 at 3:34 AM
An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR.)An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR.)
www.finanznachrichten.de - April 21 at 9:05 AM
Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los AngelesBiohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles
www.prnewswire.com - April 19 at 3:48 AM
Commit To Purchase Biohaven Pharmaceutical Holding At $17.50, Earn 6.8% Annualized Using OptionsCommit To Purchase Biohaven Pharmaceutical Holding At $17.50, Earn 6.8% Annualized Using Options
www.nasdaq.com - April 18 at 4:55 PM
Biohaven Pharmaceutical (BHVN) Lowered to Hold at Zacks Investment ResearchBiohaven Pharmaceutical (BHVN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 7:34 PM
Short Interest in Biohaven Pharmaceutical (BHVN) Increases By 97.3%Short Interest in Biohaven Pharmaceutical (BHVN) Increases By 97.3%
www.americanbankingnews.com - April 17 at 1:37 AM
-$0.87 Earnings Per Share Expected for Biohaven Pharmaceutical (BHVN) This Quarter-$0.87 Earnings Per Share Expected for Biohaven Pharmaceutical (BHVN) This Quarter
www.americanbankingnews.com - April 15 at 11:15 AM
Insider Selling: Biohaven Pharmaceutical (BHVN) Insider Sells 35,000 Shares of StockInsider Selling: Biohaven Pharmaceutical (BHVN) Insider Sells 35,000 Shares of Stock
www.americanbankingnews.com - April 12 at 7:17 PM
Biohaven Pharmaceutical (BHVN) Upgraded at Zacks Investment ResearchBiohaven Pharmaceutical (BHVN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 10 at 12:03 AM
Biohaven Pharmaceutical (BHVN) PT Lowered to $36.00 at Needham & Company LLCBiohaven Pharmaceutical (BHVN) PT Lowered to $36.00 at Needham & Company LLC
www.americanbankingnews.com - April 8 at 8:05 AM
Kleo Pharmaceuticals Selected to Present at Biotech Innovation ConferenceKleo Pharmaceuticals Selected to Present at Biotech Innovation Conference
finance.yahoo.com - April 5 at 4:37 PM
Biohaven Pharmaceutical (BHVN) Downgraded by Barclays to Equal WeightBiohaven Pharmaceutical (BHVN) Downgraded by Barclays to Equal Weight
www.americanbankingnews.com - April 5 at 11:32 AM
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific OfficerKleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
finance.yahoo.com - April 3 at 9:30 AM
Biohaven Pharmaceutical (BHVN) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowBiohaven Pharmaceutical (BHVN) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:39 PM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Recommendation of "Buy" from AnalystsBiohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 29 at 3:25 AM
Canaccord Sees An Intriguing Setup In Biohaven Following Reaction To Phase 3 NewsCanaccord Sees An 'Intriguing Setup' In Biohaven Following Reaction To Phase 3 News
www.msn.com - March 28 at 9:29 AM
Biohaven Pharmaceutical Target of Unusually High Options Trading (BHVN)Biohaven Pharmaceutical Target of Unusually High Options Trading (BHVN)
www.americanbankingnews.com - March 28 at 7:40 AM
Stock Traders Buy Large Volume of Biohaven Pharmaceutical Put Options (BHVN)Stock Traders Buy Large Volume of Biohaven Pharmaceutical Put Options (BHVN)
www.americanbankingnews.com - March 28 at 6:45 AM
Biohaven Pharmaceutical (BHVN) Rimegepant Pivotal Phase 3 Trial Results - SlideshowBiohaven Pharmaceutical (BHVN) Rimegepant Pivotal Phase 3 Trial Results - Slideshow
seekingalpha.com - March 27 at 4:33 PM
Biohaven Pharmaceutical (BHVN) Earns "Buy" Rating from Piper JaffrayBiohaven Pharmaceutical (BHVN) Earns "Buy" Rating from Piper Jaffray
www.americanbankingnews.com - March 27 at 9:43 AM
Here’s What’s Moving AnaptysBio and Biohaven PharmaceuticalHere’s What’s Moving AnaptysBio and Biohaven Pharmaceutical
finance.yahoo.com - March 27 at 9:37 AM
Biohaven Pharmaceutical (BHVN) Stock Rating Reaffirmed by Canaccord GenuityBiohaven Pharmaceutical (BHVN) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - March 26 at 9:18 PM
Heres Why Biohaven Pharmaceutical Holding Co Ltds Getting Hammered TodayHere's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today
finance.yahoo.com - March 26 at 4:32 PM
Biohaven (BHVN) Reports Positive Top-Line Results from Phase 3 Clinical Trials (BHV3000-301 & BHV3000-302) of RimegepantBiohaven (BHVN) Reports Positive Top-Line Results from Phase 3 Clinical Trials (BHV3000-301 & BHV3000-302) of Rimegepant
www.streetinsider.com - March 26 at 9:37 AM
Positive late-stage results for Biohavens rimegepant fails to lift shares, down 29% premarketPositive late-stage results for Biohaven's rimegepant fails to lift shares, down 29% premarket
seekingalpha.com - March 26 at 9:37 AM
Biohaven shares drop 23% after migraine drug trial resultsBiohaven shares drop 23% after migraine drug trial results
finance.yahoo.com - March 26 at 9:37 AM
Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN): Is Breakeven Near?Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN): Is Breakeven Near?
finance.yahoo.com - March 21 at 10:17 AM
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 SharesBiohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 Shares
www.americanbankingnews.com - March 14 at 7:12 PM
Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock OptionsImplied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options
finance.yahoo.com - March 13 at 6:31 PM
-$0.87 EPS Expected for Biohaven Pharmaceutical Holding Co Ltd (BHVN) This Quarter-$0.87 EPS Expected for Biohaven Pharmaceutical Holding Co Ltd (BHVN) This Quarter
www.americanbankingnews.com - March 12 at 11:22 AM
Biohaven Pharmaceutical (BHVN) Upgraded by Zacks Investment Research to BuyBiohaven Pharmaceutical (BHVN) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 9 at 6:49 PM

SEC Filings

Biohaven Pharmaceutical (NYSE:BHVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biohaven Pharmaceutical (NYSE:BHVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biohaven Pharmaceutical (NYSE BHVN) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.